MDEA: Difference between revisions

Line 10:

In a 1967 lab notebook entry, Alexander Shulgin briefly mentioned a colleague's report of no effect from the substance with a 100mg dose.<ref>Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin|doi=10.1111/j.1360-0443.2010.02948.x}}</ref> Shulgin later tested the compound at a range of higher doses and characterized the substance in his book [[PiHKAL]].<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>

MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy", with studies conducted in the 1990s ~~finding~~ MDEA present in approximately four percent of ecstasy tablets.<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref> In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance in on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>

In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>

MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy", with studies conducted in the 1990s having found MDEA present in approximately four percent of ecstasy tablets.<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref>

While MDEA shares many of the core entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up only in small batches synthesized and distributed by hobbyist clandestine chemists.

@@ Line 10: / Line 10: @@
 In a 1967 lab notebook entry, Alexander Shulgin briefly mentioned a colleague's report of no effect from the substance with a 100mg dose.<ref>Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin|doi=10.1111/j.1360-0443.2010.02948.x}}</ref> Shulgin later tested the compound at a range of higher doses and characterized the substance in his book [[PiHKAL]].<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>
-MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy", with studies conducted in the 1990s finding MDEA present in approximately four percent of ecstasy tablets.<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref> In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance in on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>
+In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later on August 13, 1987 under the Federal Analog Act.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref>
+MDEA is rarely sold on its own and has historically been used as an occasional additive or substitute ingredient in pills of "Ecstasy", with studies conducted in the 1990s having found MDEA present in approximately four percent of ecstasy tablets.<ref> The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA) | http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00007.x/pdf</ref>
 While MDEA shares many of the core entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up only in small batches synthesized and distributed by hobbyist clandestine chemists.